A guideline for the treatment of dementia in Japan

Internal Medicine

Volumn 43, Issue 1, 2004, Pages 18-29

  Nakamura, Shigenobu ^a  

^a Otowa Hospital   (Japan)

Author keywords

Actylcholinesterase inhibitor; Alzhemier's disease; Day service; Dementia; Donepezil; Neuroleptics

Indexed keywords

ACETOPHENAZINE; AMITRIPTYLINE; BENZODIAZEPINE; CARBAMAZEPINE; CHLORPROMAZINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; CLOMIPRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DONEPEZIL; FLUOXETINE; HALOPERIDOL; IMIPRAMINE; LOXAPINE; MAPROTILINE; NITRAZEPAM; OLANZAPINE; PAROXETINE; PENFLURIDOL; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; TACRINE; THIORIDAZINE; TIOTIXENE; TRAZODONE; TRIAZOLAM; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROIC ACID;

ALZHEIMER DISEASE; ARTICLE; BEHAVIOR THERAPY; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COGNITIVE DEFECT; DELIRIUM; DEMENTIA; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG HALF LIFE; EXTRAPYRAMIDAL SYMPTOM; HALLUCINATION; HUMAN; INCIDENCE; INSOMNIA; JAPAN; META ANALYSIS; MICTURITION DISORDER; MULTIINFARCT DEMENTIA; MUSIC THERAPY; PRACTICE GUIDELINE; RECURRENT DISEASE; SALIVATION; SIDE EFFECT; SOMNOLENCE;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DEMENTIA; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GUIDELINES; HUMANS; JAPAN; MALE; MIDDLE AGED; NOOTROPIC AGENTS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; RESEARCH; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 1142299548     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.43.18     Document Type: Article

References (47)

1. Davies P, Maloney AJ. Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2: 1403, 1976.
2. Koshimura K, Kato T, Tohyama I, Nakamura S, Kameyama M. Qualitative abnormalities of choline acetyltransferase in Alzheimer type dementia. J Neurol Sci 76: 143-150, 1986.
3. Nakamura S, Ueki A, Okamoto K, et al. A guideline for the treatment of dementia. Rinshoshinkeigaku (Clin Neurol) 42: 781-833, 2002 (in Japanese).
4. Nakamura S, Ed. Guideline for the Treatment of Patients with Dementia. World Planning, Tokyo, 2003 (in Japanese).
5. Teri L, Logsdon RG, Peskind E, et al. Alzheimer's Disease Cooperative Study. Treatment of agitation in AD. A randomized, placebo-controlled clinical trial. Neurology 55: 1271-1278, 2000.
6. Foster A, Young J, Langhorne P. Medical Day Hospital Care for the Elderly Versus Alternative Forms of Care. Cochrane Library, 2001.
7. Schneider LS, Pollock VE, Lyness SA. A metaanalysis of controlled trials of neuroleptic treatment in dementia. J Am Geriatr Soc 38: 553-563, 1990.
8. Finkel SI, Lyons JS, Anderson RL, et al. A randomized, placebo-controlled trial of thiothixene in agitated, demented nursing home patients. Int J Geriatr Psychiatr 10: 129-136, 1995.
9. Raskind MA, Sadowsky CH, Sigmund WR, Beitler PJ, Auster SB. Effect of tacrine on language, praxis, and non-cognitive behavioral problems in Alzheimer's disease. Arch Neurol 54: 836-840, 1997.
10. Devanand DP, Marder K, Michaels KS, et al. A randomized, placebo-controlled dose-comparison trial of haloperidol for psychosis and disruptive behaviors in Alzheimer's disease. Am J Psychiatry 155: 1512-1520, 1998.
11. Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 155: 54-61, 1998.
12. De Deyn PP, Rabheru K, Rasmussen A, et al. A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 53: 946-955, 1999.
13. Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M, Risperidone Study Group. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: A randomized, double-blind trial. J Clin Psychiatry 60: 107-115, 1999.
14. Reifler BV, Teri L, Raskind M, et al. Double-blind trial of imipramine in Alzheimer's disease patients with and without depression. Am J Psychiatry 146: 45-49, 1989.
15. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders. Br J Psychiatry 157: 894-901, 1990.
16. Nyth AL, Gottfries CG, Lyby K, et al. A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia. Acta Psychiatr Scand 86: 138-145, 1992.
17. Fuchs A, Hehnke U, Erhart C, et al. Video-rating analysis of effect of maprotiline in patients with dementia and depression. Pharmacopsychiatry 26: 37-41, 1993.
18. Roth M, Mountjoy CQ, Amrein R. Moclobemide in elderly patients with cognitive decline and depression: an international double-blind, placebo-controlled trial. Br J Psychiatry 168: 149-157, 1996.
19. Petracca G, Teson A, Chemerinski E, Leiguarda R, Starkstein SE. A double-blind, placebo-controlled study of clomipramine in depressed patients with Alzheimer's disease. J Neuropsychiatr Neurosci 8: 270-275, 1996.
20. Taragano FE, Lyketsos CG, Mangone CA, Allegri RF, Comesana-Diaz E. A double-blind, randomized, fixed-dose trial of fluoxetine vs amitriptyline in the treatment of major depression complicating Alzheimer's disease. Psychosomatics 38: 246-252, 1997.
21. Katona CLE, Hunter BN, Bray J. A double-blind comparison of the efficacy and safety of paroxetine and imipramine in the treatment of depression with dementia. Int J Geriatr Psychiatry 13: 100-108, 1998.
22. Magai C, Kennedy G, Cohen CI, Gomberg D. A controlled clinical trial of sertraline in the treatment of depression in nursing home patients with late stage Alzheimer's disease. Am J Geriatr Psychiatry 8: 66-74, 2000.
23. Rogers SL, Friedhoff LT, The Donepezil Study Group. The efficacy and safety of donepezil in patients with Alzheimer's disease: results of a US Multicentre, randomized, double-blind, placebo-controlled trial. Dementia 7: 293-303, 1996.
24. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT, The Donepezil Study Group. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 50: 136-145, 1998.
25. Rogers SL, Doody RS, Mohs RC, Friedhoff LT, The Donepezil Study Group. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 158: 1021-1031, 1998.
26. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 10: 237-244, 1999.
27. Homma A, Takeda M, Imai Y, et al, E2020 Study Group. Clinical efficacy and safety of donepezil on cognitive and global function in patients with Alzheimer's disease. A 24-week, multicenter, double-blind, placebo-controlled study in Japan. Dement Geriatr Cogn Disord 11: 299-313, 2000.
28. Mohs RC, Doody RS, Morris JC, et al, "312" Study Group. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57: 481-488, 2001.
29. Winblad B, Engedal K, Soininen H, et al, Donepezil Nordic Study Group. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57: 489-495, 2001.
30. Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease. Neurology 57: 613-620, 2001.
31. Geldmacher P, Berger F, Sramko C, Frolich L. Effect of donepezil treatment on visual attention/exploration tasks in patients with Alzheimer's disease: results of the pilot study. Neurobiol Aging 21 (1-S): PS169, 2001.
32. Tariot PN, Cummings JL, Katz IR, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home settings. J Am Geriat Soc 49: 1590-1599, 2001.
33. Doody RS, Dunn JK, Clark CM, et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. Dement Geriatr Cogn Disord 12: 295-300, 2001.
34. Gauthier S, Feldman H, Hecker J, Vellas B, Emir B, Subbiah P. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease. Curr Med Res Opin 18: 347-354, 2002.
35. Wimo A, Winblad B, Engedal K, et al, Donepezil Nordic Study Group. An economic evaluation of donepezil in mild to moderate Alzheimer's disease. - Results of a year, double-blind, randomized trial -. Dement Geriatr Cogn Disord 15: 44-54, 2003.
36. Hasegawa K, Homma A, Takeda M, et al. Evaluation of impression by family or caregivers on patients with Alzheimer-type dementia: Can donepezil improve a communication of patients with family?. Geriat Med 41: 733-743, 2003 (in Japanese).
37. Birks J, Grimley Evans J, Iakovidou V, Tsolaki M. Rivastigmine for Alzheimer's Disease. Cochrane Library, 2001.
38. Olin J, Schneider L. Galantamine for Alzheimer's Disease. Cochrane Library, 2001.
39. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308: 81-106, 1994.
40. PROGRESS Collabolative Group. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease. Arch Intern Med 163: 1069-1075, 2003.
41. Moore WS, Barnett HJM, Beebe HG, et al, American Heart Association. Guidlines for carotid endarterectomy. A multidisciplinary consensus statement from the Ad Hoc Committee. Stroke 26: 188-201, 1995.
42. Gotoh F, Tohgi H, Hirai S, et al. Cilostazol stroke prevention study: A placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovascular Diseases 9: 147-157, 2000.
43. Fioravanti M, Yanagi M. Cytidine Diphosphocholine (CDP Choline) for Cognitive and Behavioural Disturbances Associated with Chronic Cerebral Disorders in the Elderly. Cochrane Library, 2000.
44. McKeith IG, Grace JB, Walker Z, et al. Rivastigmine in the treatment of dementia with Lewy bodies: preliminary findings from an open trial. Int J Geriatr Psychiatry 15: 387-392, 2000.
45. Campbell S, Stephens S, Ballard C. Dementia with Lewy bodies. Clinical features and treatment. Drugs Aging 18: 397-407, 2001.
46. Neary D, Snowden JS, Gustafson L, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51: 1546-1554, 1998.
47. Swartz JP, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin Psychiatry 58: 212-216, 1997.